Increased CSF F2-isoprostane concentration in probable AD

Neurology

Volumn 52, Issue 3, 1999, Pages 562-565

  Montine, Thomas J ^a,b   Beal, M F ^c   Cudkowicz, M E ^c   O'Donnell, H ^c   Margolin, R A ^a   McFarland, L ^a   Bachrach, A F ^d   Zackert, W E ^b   Roberts, L J ^a,b   Morrow, J D ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MALE; NERVE DEGENERATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; AMYOTROPHIC LATERAL SCLEROSIS; CEREBROSPINAL FLUID; STATISTICAL MODEL;

8,12 ISO ISOPROSTANE F2ALPHA III; 8,12-ISO-ISOPROSTANE F2ALPHA-III; DRUG DERIVATIVE; PROSTAGLANDIN F2 ALPHA;

AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DINOPROST; FEMALE; HUMANS; LINEAR MODELS; MALE;

EID: 0032588611     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.3.562     Document Type: Article

References (12)

1. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995;38:357-366.
2. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-147.
3. Tu PH, Gurney ME, Julien JP, et al. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Lab Invest 1997;76:441-456.
4. Gutteridge JMC, Westermarck T, Halliwell B. Oxygen radical damage in biological systems. In: Johnson JE, Walford R, Harmon D, Miguel J, eds. Free radicals, aging, and degenerative diseases. New York: Alan R. Liss, 1986:99-139.
5. Ronald and Nancy Reagan Institute of the Alzheimer's Association and National Institute on Aging Working Group on Biological Markers of Alzheimer's Disease. Consensus report on the Working Group on "Molecular and Biochemical Markers of Alzheimer's Disease." Neurobiol Aging 1998;19:109-116.
6. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997;36:1-21.
7. 2α-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci USA 1998; 95:3449-3454.
8. 2-isoprostanes are increased in Alzheimer's disease. Ann Neurol 1998;44:410-413.
9. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group Under the Auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
10. Ortof E, Crystal HA. Rate of progression of Alzheimer's disease. J Am Geriatr Soc 1989;37:511-514.
11. Harman D. Free radical theory of aging: role of free radicals in the orientation and evolution of life, aging, and disease processes. In: Johnson JE, Walford R, Harmon D, Miguel J, eds. Free radicals, aging, and degenerative diseases. New York: Alan R. Liss, 1986:99-139.
12. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-2074.